We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > InnoCare Pharma

News List

10 Studies on InnoCare’s Oncology Pipelines Selected at the Upcoming 65th Annual Meeting of ASH PharmaSources
November 15, 2023
InnoCare Pharma,announced today that 10 studies from InnoCare's oncology pipeline were selected for presentation at the 65th American Society of Hematology (ASH) Annual Meeting on December 9-12, 2023 in San Diego, California, United States.
InnoCare Pharma announced 2023 interim results as of 30 June 2023 PharmaSources
September 04, 2023
InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced 2023 interim results as of 30 June 2023.
InnoCare Announces Approval of Clinical Trial of pan-TRK Inhibitor Zurletrectinib for the Treatment of Pediatric Patients in China PharmaSources
July 27, 2023
InnoCare announces approval of clinical trial of pan-TRK inhibitor Zurletrectinib for the treatment of pediatric patients in China.